Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Sandrine Niyongere"'
Autor:
Elizabeth M. Corley, Moaath K. Mustafa Ali, Hanan Alharthy, Kathryn A. F. Kline, Danielle Sewell, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Ashkan Emadi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Acute myeloid leukemia (AML) is the common type of acute leukemia in adults. Definitive prognostic significance of variants of unknown significance lacks for many commonly mutated genes, including the isocitrate dehydrogenase 1 (IDH1) synonymous sing
Externí odkaz:
https://doaj.org/article/9ef9917eeaff4198b6ee6ac95bdbd640
Autor:
Moaath K. Mustafa Ali, Elizabeth M. Corley, Hanan Alharthy, Kathryn A. F. Kline, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Ashkan Emadi, Maria R. Baer
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
There is a deficiency of real-world data on the impact of combining venetoclax (VEN) with hypomethylating agents (HMAs) in newly diagnosed acute myeloid leukemia (AML) patients. We conducted a single-center, propensity-adjusted retrospective cohort s
Externí odkaz:
https://doaj.org/article/a8829a8dd74a40fc9b48d7be3211c6d6
Autor:
Michael E. Kallen, Rima Koka, Zeba N. Singh, Yi Ning, Mehmet H. Kocoglu, Ashraf Z. Badros, Sandrine Niyongere, Vu H. Duong, Ashkan Emadi, Maria R. Baer
Publikováno v:
Leukemia Research Reports, Vol 18, Iss , Pp 100358- (2022)
New therapies for multiple myeloma have improved outcomes, but are associated with therapy-related hematologic malignancies. We report eight patients with therapy-related B-lymphoblastic leukemias (t-B-ALL) in the setting of therapy for multiple myel
Externí odkaz:
https://doaj.org/article/33542464236147448d22605a7dccfcab
Autor:
Elizabeth M. Corley, Moaath K. Mustafa Ali, Hanan Alharthy, Kathryn A. F. Kline, Danielle Sewell, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Ashkan Emadi
Publikováno v:
Biology, Vol 11, Iss 6, p 916 (2022)
The prognostic significance of the length of internal tandem duplication (ITD) insertions in mutant FLT3 genes in acute myeloid leukemia (AML) is controversial. We conducted a retrospective study to evaluate the correlation between the ITD base-pair
Externí odkaz:
https://doaj.org/article/fbf159d98cb04bc387a16b1456e002ca
Autor:
Sandrine Niyongere, Aaron P. Rapoport
Publikováno v:
Haematologica, Vol 106, Iss 5 (2021)
Externí odkaz:
https://doaj.org/article/81763248dbe947f78667e8b67750433a
Autor:
Sandrine Niyongere, Gabriela Sanchez-Petitto, Jack Masur, Maria R. Baer, Vu H. Duong, Ashkan Emadi
Publikováno v:
Pharmaceuticals, Vol 13, Iss 6, p 124 (2020)
Outcomes of acute lymphoblastic leukemia (ALL) in older adults treated with chemotherapy are poor. The CD19/CD3 bispecific T-cell engager (BiTE) antibody blinatumomab is approved for refractory, relapsed or minimal/measurable residual disease (MRD)-p
Externí odkaz:
https://doaj.org/article/1cd08a30052f417a87f123d7935174f6
Autor:
Moaath K. Mustafa Ali, Matthew T. Williams, Elizabeth M. Corley, Fahad AlKaabba, Sandrine Niyongere
Publikováno v:
Leukemia & Lymphoma. :1-10
Autor:
Maria R. Baer, Goutham Narla, Danilo Perrotti, Yin Wang, Jaya Sangodkar, Sandrine Niyongere, Rena G. Lapidus, Shivani Kapoor, Jonelle K. Lee, Christopher M. Bailey, Prerna Singh, Mario Scarpa
Supplementary Table S1. AML patients. Supplementary Table S2. RT-qPCR primers. Supplementary Table S3. IC50 concentrations (nM) of FLT3 inhibitors, PP2A activators and GSK-3beta inhibitors. Supplementary Figure S1. Concurrent PP2A-activating drug tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86eb9d3fab43e2d25f4450c2f3c42655
https://doi.org/10.1158/1535-7163.22522443
https://doi.org/10.1158/1535-7163.22522443
Autor:
Maria R. Baer, Goutham Narla, Danilo Perrotti, Yin Wang, Jaya Sangodkar, Sandrine Niyongere, Rena G. Lapidus, Shivani Kapoor, Jonelle K. Lee, Christopher M. Bailey, Prerna Singh, Mario Scarpa
Fms-like tyrosine-like kinase 3 internal tandem duplication (FLT3-ITD) is present in acute myeloid leukemia (AML) in 30% of patients and is associated with short disease-free survival. FLT3 inhibitor efficacy is limited and transient but may be enhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2921d1b6556415df736f52ed8b400ce1
https://doi.org/10.1158/1535-7163.c.6543381.v1
https://doi.org/10.1158/1535-7163.c.6543381.v1
Autor:
Feyruz V. Rassool, Stephen B. Baylin, Benjamin A. Youngblood, Casey L. O'Connell, Sandrine Niyongere, Ashkan Emadi, Vu H. Duong, Rena G. Lapidus, Tian Mi, Søren M. Bentzen, Aksinija A. Kogan, Maria R. Baer
Supplementary Figure from Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::184b892f8dad09262cb4602b1a568d6f
https://doi.org/10.1158/1078-0432.22487766.v1
https://doi.org/10.1158/1078-0432.22487766.v1